Pro or con? Anorexia nervosa and the internet von Chesley, Eric B., Alberts, J.D., Klein, J.D., Kreipe, R.E.

Volltext

Body composition changes during recovery from anorexia nervosa: comparison of two dietary regimes von Forbes, GB, Kreipe, RE, Lipinski, BA, Hodgman, CH

Volltext

Menstruation and fertility following anorexia nervosa von SHOMENTO, S. H, KREIPE, R. E

Volltext

Comparison of two hospital treatment programs for anorexia nervosa von Kreipe, R.E, Kidder, F

Volltext

The food exchange system in the treatment of anorexia nervosa von Kreipe, R.E, Trott, M

Volltext

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression von Nitz, U., Gluz, O., Huober, J., Kreipe, H.H., Kates, R.E., Hartmann, A., Erber, R., Scholz, M., Lisboa, B., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Weiss, E., Böhmer, S., Kreienberg, R., Du Bois, A., Sattler, D., Thomssen, C., Kiechle, M., Jänicke, F., Wallwiener, D., Harbeck, N., Kuhn, W.

Volltext

LBA17 Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early... von Gluz, O., Nitz, U.A., Christgen, M., Kummel, S., Holtschmidt, J., Schumacher, J., Hartkopf, A.D., Luedtke-Heckenkamp, K., Just, M., von Schumann, R., Polata, S., Schinköthe, T., Graeser-Mayer, M.K., Kates, R.E., Würstlein, R., Kreipe, H., Harbeck, N.

Volltext

LBA24 Multiparametric prognostic score in early HR+/HER2- breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology von Gluz, O., Christgen, M., zu Eulenburg, C., Nitz, U.A., Kummel, S., Braun, M., Aktas, B., Luedtke-Heckenkamp, K., Forstbauer, H., Grischke, E-M., Schumacher, C., Baehner, R.F.L., Kates, R.E., Graeser, M., Würstlein, R., Kreipe, H., Harbeck, N.

Volltext

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplati... von Gluz, O., Nitz, U., Liedtke, C., Christgen, M., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Lindner, C., Kümmel, S., Kates, R.E., Potenberg, J., Staib, P., Wuerstlein, R., Kreipe, H.H., Harbeck, N.

Volltext

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial von Gluz, O., Liedtke, C., Huober, J., Peyro-Saint-Paul, H., Kates, R.E., Kreipe, H.H., Hartmann, A., Pelz, E., Erber, R., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Thomssen, C., Jänicke, F., Kiechle, M., Wallwiener, D., Kuhn, W., Nitz, U., Harbeck, N.

Volltext

LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcyc... von Gluz, O., Nitz, U.A., Christgen, M., Kuemmel, S., Braun, M., Thill, M., Aktas, B., Wimberger, P., Luedtke-Heckenkamp, K., Zaiss, M., Warm, M., Schumacher, C., Schem, C., Graeser, M., Hartkopf, A.D., Kates, R.E., Eulenburg, C. zu, Schmid, P., Kreipe, H., Harbeck, N.

Volltext

LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast c... von Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Biehl, C.M., Schumacher, C., Malter, W., Aktas, B., Forstbauer, H., Tio, J., Grischke, E-M., Kolberg-Liedtke, C., de Haas, S., Deurloo, R.J., Kates, R.E., Eulenburg zu, C., Wuerstlein, R., Kreipe, H., Gluz, O.

Volltext

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 ex... von Nitz, U, Gluz, O, Huober, J, Kreipe, H H, Kates, R E, Hartmann, A, Erber, R, Moustafa, Z, Scholz, M, Lisboa, B, Mohrmann, S, Möbus, V, Augustin, D, Hoffmann, G, Weiss, E, Böhmer, S, Kreienberg, R, Du Bois, A, Sattler, D, Thomssen, C, Kiechle, M, Jänicke, F, Wallwiener, D, Harbeck, N, Kuhn, W

Volltext

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial von Gluz, O, Nitz, U, Kreipe, H.H, Christgen, M, Kates, R.E, Hofmann, D, Shak, S, Clemens, M, Kraemer, S, Aktas, B, Kuemmel, S, Reimer, T, Kusche, M, Heyl, V, Lorenz-Salehi, F, Just, M, Liedtke, C, Wuerstlein, R, Harbeck, N

Volltext

P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX® : results from the WSG PlanB trial von Nitz, U, Christgen, O. Gluz,H. Kreipe,M, Clemens, R.E. Kates,M, Kraemer, S, Aktas, B, Kuemmel, S, Harbeck, N

Volltext

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study von Gluz, O, Nitz, U, Christgen, M, Kreipe, H, Kates, R.E, Kuemmel, S, Braun, M, Schumacher, C, Wuerstlein, R, Harbeck, N

Volltext

121P Endocrine response assessment in HR+ HER2- early breast cancer: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial von Hamann, M., Gluz, O., Christgen, M., Nitz, U.A., Kummel, S., Braun, M., Thill, M., Würstlein, R., Wimberger, P., Hartkopf, A.D., Schem, C., Zaiss, M., Graeser-Mayer, M.K., Kates, R.E., Eulenburg, C. Zu, Jozwiak, K., Burmeister, S., Baehner, R.F.L., Kreipe, H., Harbeck, N.

Volltext

Corrections to “Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 ex... von Nitz, U., Gluz, O., Huober, J., Kreipe, H.H., Kates, R.E., Hartmann, A., Erber, R., Moustafa, Z., Scholz, M., Lisboa, B., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Weiss, E., Böhmer, S., Kreienberg, R., Du Bois, A., Sattler, D., Thomssen, C., Kiechle, M., Jänicke, F., Wallwiener, D., Harbeck, N., Kuhn, W.

Volltext

11O Prospective Comparison of Risk Assessment Tools in Early Breast Cancer: Correlation Analysis from the Phase III Wsg-Plan B Trial von Gluz, O., Kreipe, H.H., Degenhardt, T., Salem, M., Kates, R.E., Shak, S., Svedman, C., Liedtke, C., Nitz, U., Harbeck, N.

Volltext